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High Central Pulse Pressure Is Independently
Associated With Adverse Cardiovascular Outcome
The Strong Heart Study
Mary J. Roman, MD,* Richard B. Devereux, MD,* Jorge R. Kizer, MD, MSC,* Peter M. Okin, MD,*
Elisa T. Lee, PHD,† Wenyu Wang, PHD,† Jason G. Umans, MD, PHD,‡ Darren Calhoun, PHD,‡
Barbara V. Howard, PHD‡
New York, New York; Oklahoma City, Oklahoma; and Washington, DC
Objectives This study was designed to facilitate clinical use of central pulse pressure (PP). We sought to determine a value
that might predict adverse outcome and thereby provide a target for assessment of intervention strategies.
Background We previously documented that central PP more strongly relates to carotid hypertrophy and extent of atheroscle-
rosis and, more importantly, better predicts incident cardiovascular disease (CVD) than brachial PP.
Methods Radial applanation tonometry was performed in the third Strong Heart Study examination to determine central
blood pressure. Cox regression analyses were performed using pre-specified covariates and quartiles of central
and brachial PP.
Results Among 2,405 participants without prevalent CVD, 344 suffered CVD events during 5.6  1.7 years. Quartiles of
central PP (p  0.001) predicted outcome more strongly than quartiles of brachial PP (p  0.052). With adjust-
ment for covariates, only the event rate in the fourth quartile of central PP (50 mm Hg) was significantly
higher than that in the first quartile (hazard ratio [HR]: 1.69, 95% confidence interval [CI]: 1.20 to 2.39, p 
0.003). Central PP 50 mm Hg was related to outcome in both men (HR: 2.06, 95% CI: 1.39 to 3.04, p 
0.001) and women (HR: 2.03, 95% CI: 1.55 to 2.65, p  0.001); in participants with (HR: 1.84, 95% CI: 1.41 to
2.39, p  0.001) and without diabetes (HR: 1.91, 95% CI: 1.29 to 2.83, p  0.001); and in individuals younger
(HR: 2.51, 95% CI: 1.59 to 3.95, p  0.001) and older (HR: 1.53, 95% CI: 1.19 to 1.97, p  0.001) than the age
of 60 years.
Conclusions Central PP 50 mm Hg predicts adverse CVD outcome and may serve as a target in intervention strategies if
confirmed in other populations and in prospective studies. (J Am Coll Cardiol 2009;54:1730–4) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.070s
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pentral (aortic) and brachial (peripheral) systolic and pulse
ressures differ due to pulse wave amplification, a function
f vascular compliance and wave reflection (1). The differ-
nce between central and brachial systolic and pulse
ressures decreases with age and other cardiovascular
isease (CVD) risk factors that cause vascular stiffening
2,3). Central arterial pressure more closely reflects the
oad placed on the left ventricle and the coronary and
erebral vasculature. Thus, central blood pressure (BP)
rom the *Division of Cardiology, Weill Cornell Medical College, New York, New
ork; †Center for American Indian Health Research, University of Oklahoma Health
ciences Center, Oklahoma City, Oklahoma; and the ‡Medstar Research Institute,
ashington, DC. Supported by grants (HL41642, HL41652, HL41654, HL65521)
rom the National Heart, Lung, and Blood Institute. Dr. Kizer has received grant
upport from DiaDexus, Inc. and serves on the Speakers’ Bureau for Merck and Co.w
Manuscript received March 4, 2009; revised manuscript received May 14, 2009,
ccepted May 25, 2009.hould be a more accurate marker of risk and an appro-
riate target for assessment of efficacy of intervention
trategies.
In the population-based SHS (Strong Heart Study) trial,
e demonstrated that pulse pressure (PP) was more strongly
elated to vascular hypertrophy and extent of atherosclerosis
han was systolic pressure and that central PP was more
trongly related to these subclinical manifestations of CVD
han was brachial PP (4). More importantly, central PP as
continuous variable better predicted incident CVD than
id brachial PP. We subsequently reported similar findings
n a separate population-based study of elderly community-
welling individuals living in Dicomano, Italy (5). However,
o facilitate use of central PP in intervention strategies and
linical practice, a value that may be of clinical utility in
redicting adverse clinical outcome is needed. To this end,
e have extended follow-up of SHS participants for an
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October 27, 2009:1730–4 Central Pulse Pressure and Cardiovascular Outcomedditional year and examined the relation of quartiles of
rachial and central PPs to cardiovascular outcomes.
ethods
tudy population. The SHS study is a population-based,
ongitudinal study of prevalent and incident CVD in Amer-
can Indians that began in 1989. Details of the study design
ave been previously published (6). At the third examina-
ion (1997 to 1999), radial artery applanation tonometry to
stimate central BP was added to the study protocol.
Blood was drawn following a 12-h fast to determine
ipids, fasting plasma glucose, creatinine, and fibrinogen.
iabetes was defined by the American Diabetes Association
riteria (7) as fasting plasma glucose 7.0 mmol/l (126
g/dl) or by use of hypoglycemic treatment. Brachial BP
as measured in triplicate in the right arm by cuff and
ercury sphygmomanometer after the participant had
ested in a seated position for 5 min; the average of the last
measurements was used as brachial BP. Then, PP was
alculated as the difference between systolic and diastolic
ressures. Hypertension was defined by the criteria of the
eventh Report of the Joint National Committee (8) as
ystolic pressure 140 mm Hg, diastolic pressure 90 mm
g, or current use of antihypertensive medication.
Participants free of clinically overt CVD, including atrial
brillation, at the third SHS study examination were in-
luded in analyses. The occurrence of fatal and nonfatal
VD events (myocardial infarction, coronary heart disease,
udden death, congestive heart failure, and stroke) was
abulated during follow-up, as previously described (9,10).
he CVD events were determined from medical records,
utopsy reports, and informant interviews; all materials were
ndependently reviewed by physician members of the SHS
tudy’s morbidity and mortality committees. Follow-up
hrough December 2005 was 99.8% complete for mortality
nd 99.2% complete for morbid events. The Indian Health
ervice Institutional Review Board and institutional review
oards of the participating institutions and participating
ribes approved the study; informed consent was obtained
rom all participants.
pplanation tonometry. As previously described (4), ra-
ial arterial pressure waveforms were obtained by applana-
ion tonometry using the SphygmoCor device (AtCor
edical, Sydney, Australia). Applanation tonometry has
een validated to yield accurate estimates of intra-arterial
P by comparison with simultaneous invasive pressure
ecordings (11,12).
tatistical analyses. Data are presented as mean  SD.
eans of continuous variables were compared using the
tudent t test for independent samples. Categorical vari-
bles were compared by chi-square analysis. Relations of
uartiles of central and brachial PP to cardiovascular events
ere determined in Cox regression analyses. Logistic re-
ression analysis was performed to determine the indepen-
ent correlates of central PP 50 mm Hg. Differences in bystolic and diastolic pressures
cross PP quartiles were assessed
y analysis of variance. Two-
ailed p  0.05 was considered
ignificant. Statistical analyses
ere performed with SPSS ver-
ion 12.0 (SPSS Inc., Chicago,
llinois).
esults
opulation characteristics and CVD outcomes. Among
he 2,405 participants free of prevalent CVD at the time of
xamination, 344 suffered fatal and nonfatal CVD events
61 myocardial infarctions, 163 definite coronary heart
iseases, 49 strokes, 71 congestive heart failures) during a
ean follow-up of 5.6  1.7 years. Mean age was 63  8
ears (range 51 to 84 years), 65% were women, and body
ass index was 31.3  6.6 kg/m2. Hypertension was
resent in 52% of the population, of whom 68% were taking
ntihypertensive medications. Diabetes was present in 47%
f the population, and 28% were active smokers.
uartiles of PP and CVD outcomes. Cox regression
odels of traditional CVD risk factors and quartiles of
rachial and central PP are presented in Table 1. Quartiles
f central PP (p  0.001) were much more predictive of
utcome than quartiles of brachial PP (p  0.052). Event
ates in the first to fourth quartiles of central PP were
1.0%, 9.9%, 15.0%, and 21.3% (p 0.001 for trend). With
djustment for covariates, only the hazard rate in the fourth
uartile (central PP 50 mm Hg) was significantly higher
han that in the first quartile (hazard ratio [HR]: 1.69, 95%
onfidence interval [CI]: 1.20 to 2.39, p  0.003). Event
ates in the fourth quartile were likewise significantly higher
han in the second quartile (p  0.001) and tended to be
igher than in the third quartile (p  0.066). Furthermore,
he hazard rate in the fourth quartile was significantly higher
han that of the other quartiles combined (HR: 1.57, 95% CI:
.22 to 2.02, p  0.001). Hazards ratios for quartiles of
rachial and central PPs are depicted in Figure 1. Addition of
se of antihypertensive medications or substitution of high-
nd low-density lipoprotein cholesterol for the ratio in
econdary analyses did not alter results. Furthermore, addi-
ion of indicator variables for use of either beta-blocking
gents or statins did not alter results. Across both central
nd brachial PP quartiles, there were significant stepwise
ncreases in systolic (p  0.001) but not diastolic pressures
p  0.20, data not shown).
orrelates of central PP >50 mm Hg. Significant differ-
nces between the fourth quartile and the other quartiles led
s to perform additional analyses focusing on this quartile
Table 2). In multivariable analysis, central PP50 mm Hg
as independently related to female sex, age, plasma creat-
nine, the presence of diabetes and hypertension (or brachial
ystolic pressure), and lower body mass index and heart rate,
Abbreviations
and Acronyms
BP  blood pressure
CVD  cardiovascular
disease
PP  pulse pressureut not to current smoking, fibrinogen, or cholesterol/high-
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Central Pulse Pressure and Cardiovascular Outcome October 27, 2009:1730–4ensity lipoprotein ratio. Central PP 50 mm Hg (com-
ared with 50 mm Hg) was significantly related to
utcome in both men and women, in participants with and
ithout diabetes, and in individuals older and younger than
he ages of both 60 and 65 years (Table 3).
omparison of brachial and central PP quartiles. As
hown in Table 1, both brachial and central PPs increased
y roughly 10 mm Hg per quartile. In addition, there was a
trong correlation between brachial and central PP (r 
.67, p  0.001). However, as shown in the box plots in
igure 2, there was substantial overlap of brachial PPs
etween quartiles of central PP. Furthermore, only 61% of
ndividuals in the highest brachial PP quartile fell within the
ighest central PP quartile and only 58% of individuals in
he lowest brachial PP quartile fell within the lowest central
P quartile.
ultivariable Cox Regression Models of Relation of Traditionalisk F ctors and Cent al and Brachial PP Quartiles to CardiovascuTable 1 Multivariable Cox Regression Models of Rel ti of TraRisk Factors and Central and Brachial PP Quartiles to
Variable HR (95% CI)
Age, yrs 1.054 (1.037–1.070)*
Male, % 1.212 (0.948–1.50)
BMI, kg/m2 0.987 (0.968–1.006)
Current smoking, % 1.372 (1.052–1.788)†
Cholesterol/HDL 1.058 (0.988–1.133)
Creatinine, mg/dl 1.172 (1.094–1.256)*
Fibrinogen, mg/dl 1.001 (1.000–1.002)‡
Diabetes mellitus, % 2.536 (1.974–3.258)*
Heart rate, beats/min 1.014 (1.004–1.024)‡
Brachial PP quartiles 1.117 (0.999–1.248)
First quartile (45 mm Hg)
Second quartile (46–54 mm Hg) 1.052 (0.738–1.499)
Third quartile (55–66 mm Hg) 1.210 (0.860–1.704)
Fourth quartile (67 mm Hg) 1.370 (0.967–1.942)
p  0.001; †p  0.05; ‡p  0.01; §p  0.005.
BMI  body mass index; HDL  high-density lipoprotein; PP  pulse pressure.
Figure 1 Hazards Ratios for Incident Cardiovascular Event
Hazards ratios for incident cardiovascular events in 2,405 individuals initially
free of clinical cardiovascular disease are stratified by quartiles of brachial
(hatched bars) and central aortic (solid bars) pulse pressures (PPs). Quartiles
of central PP (p  0.001) predicted outcome more strongly than quartiles of
brachial PP (p  0.052). Only the event rate in the fourth central PP quartile
(PP 50 mm Hg) was significantly higher than in the first quartile (p  0.003). *iscussion
he present study documents the superiority of central over
rachial PP for prediction of cardiovascular events in the
HS study population and suggests a value that might be of
linical utility if confirmed in other populations and in
rospective studies. Importantly, this value, derived from
he distribution within our study population rather than
rom a formal, adequately-powered analysis to determine a
hreshold of increased risk, performed well in clinically
elevant subsets of the SHS study population suggesting
hat it is robust and not based on skewed distribution.
From a pathophysiologic perspective, it is not surprising
hat central BP better correlates with target organ damage
nd cardiovascular outcomes than brachial BP does because
t more accurately reflects vascular load on the left ventricle
nd cerebral and coronary vasculature. This concept has
utcomenal
iovascular Outcome
Variable HR (95% CI)
Age, yrs 1.051 (1.035–1.067)*
Male, % 1.266 (0.990–1.620)
BMI, kg/m2 0.990 (0.971–1.009)
Current smoking, % 1.355 (1.041–1.763)†
Cholesterol/HDL 1.062 (0.991–1.138)
Creatinine, mg/dl 1.164 (1.086–1.247)*
Fibrinogen, mg/dl 1.001 (1.000–1.002)†
Diabetes mellitus, % 2.48 (1.931–3.186)*
Heart rate, beats/min 1.018 (1.008–1.029)§
Central PP quartiles 1.229 (1.098–1.376)*
First quartile (31 mm Hg)
Second quartile (32–39 mm Hg) 0.89 (0.62–1.29)
Third quartile (40–49 mm Hg) 1.28 (0.91–1.82)
Fourth quartile (50 mm Hg) 1.69 (1.20–2.39)§
omparison of Demographic Variables andardiovascular isease Risk F ctors in Participantsith Centra PP <50 mm Hg Versu >50 mm Hg
Table 2
Compari on of Demographic Variables and
Cardiovascular Disease Risk Factors in Participants
With Central PP <50 mm Hg Versus >50 mm Hg
Variable
PP <50 mm Hg
(n  1,791)
PP >50 mm Hg
(n  614) p Value
Age, yrs 61.6 7.0 66.6 8.0 0.001
Male, % 38.7 23.7 0.001
BMI, kg/m2 31.5 6.8 30.9 6.1 0.049
Hypertension, % 43.3 77.2 0.001
Diabetes mellitus, % 44.9 53.5 0.001
Current smoking, % 29.5 22.1 0.001
Brachial SBP, mm Hg 126 16 146 21 0.001
Brachial DBP, mm Hg 75 10 74 11 0.126
Brachial PP, mm Hg 51 13 73 18 0.001
Heart rate, beats/min 70 11 66 10 0.001
Total/HDL cholesterol 4.8 1.5 4.6 1.5 0.016
Creatinine, mg/dl 0.8 (0.2) 0.8 (0.3) 0.004*
Fibrinogen, mg/dl 380 121 396 126 0.007lar Oditio
CardCompared by Mann-Whitney U test and reported as median (interquartile range).
DBP  diastolic blood pressure; SBP  systolic blood pressure; other abbreviations as in Table 1.
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October 27, 2009:1730–4 Central Pulse Pressure and Cardiovascular Outcomenly recently been possible to test with the development of
ccurate noninvasive techniques permitting pulse wave anal-
sis and determination of central BP (11–13). Thus, several
mall studies in select populations have documented stron-
er relations of central than brachial BP to carotid artery
ntima-media thickness (14), severity of coronary artery
isease (15), and all-cause mortality in patients with end-
tage renal disease (16). In the large, population-based SHS
tudy, central pressure, particularly PP, was more strongly
elated to vascular hypertrophy and extent of atherosclerosis,
s well as to incident CVD, than was brachial pressure (4).
his observation has been confirmed in another population-
ased study (ICARe [Insufficienza Cardiaca negli Anziani
esidenti] Dicomano Study) of elderly individuals (5),
espite the decrease in pressure amplification with age and
ssociated lesser difference, on average, between central and
rachial pressures.
Furthermore, reduction of central pressure may add to
eduction of brachial pressure in improving clinical outcome
n the treatment of hypertension. In the CAFE (Conduit
rtery Function Evaluation) substudy of the ASCOT
Anglo-Scandinavian Cardiac Outcomes Trial) hyperten-
ion trial (17), brachial BP was reduced to a similar extent in
oth the atenolol with/without thiazide and amlodipine
ith/without perindopril arms, whereas central systolic and
ulse pressures were reduced significantly more by
mlodipine-based treatment. Both brachial and central PPs
ere similarly related (chi square  4.1 for both) to a
ost-hoc–defined composite outcome (new cardiovascular
vents, cardiovascular procedures, renal impairment) inde-
endent of other risk factors (17). It is uncertain whether
he more favorable outcome associated with the amlodipine-
ased arm in the overall ASCOT (18) was related to the
reater central BP lowering with this regimen. This possi-
ility, however, is supported by observations that benefi-
ial effects of regimens based on calcium-channel and
ngiotensin-receptor blockade therapy on outcome were
erformance of Central PP >50 mm Hg forredictio of Cardiovascular Outco e inopulatio Subsets
Table 3
Performance of Central PP >50 mm Hg for
Prediction of Cardiovascular Outcome in
Population Subsets
Variable n HR (95% CI) p Value
Interaction
p Value
Sex 0.94
Men 838 2.06 (1.39–3.04) 0.001
Women 1,567 2.03 (1.55–2.65) 0.001
Diabetes mellitus 0.98
Absent 1,259 1.91 (1.29–2.83) 0.001
Present 1,122 1.84 (1.41–2.39) 0.001
Age, yrs
60 994 2.51 (1.59–3.95) 0.001
0.079
60 1,411 1.53 (1.19–1.97) 0.001
65 1,559 1.91 (1.39–2.64) 0.001
0.47
65 846 1.64 (1.20–2.22) 0.002
I  confidence interval; PP  pulse pressure.ndependent of lowering of brachial BP (19,20).The findings of the current study complement the recent
eport from the Anglo-Cardiff Collaborative Trial II (2),
herein levels of brachial systolic pressure based on BP
lassifications were compared with aortic systolic pressures
n 6,779 healthy normotensive or untreated hypertensive
ndividuals. There was substantial overlap of aortic systolic
ressures between individuals with normal or high normal
ressures and those with stage 1 hypertension based on
rachial systolic pressure, indicating that central systolic
ressure cannot be inferred from brachial systolic pressure.
hese data also indicate the potential for undertreatment or
vertreatment of hypertension based on brachial BP targets,
f indeed central BP is a more accurate marker of risk. Our
ata provide further confirmation of the inability to accu-
ately estimate central pressure from brachial pressure.
tudy limitations. The independent prognostic utility of
entral PP needs to be confirmed in larger studies with more
utcome events in which it will be possible to apply more
ormal methods for threshold estimation and to assess
ormally the costs and benefits of treatment based on such
ut points. Whereas our study population is limited to
merican Indians, our findings are likely to be highly
pplicable to the general U.S. population given its increas-
ng prevalence of obesity and diabetes. Furthermore, the
ame traditional risk factors for CVD in the general U.S.
opulation have been shown to be operative in the SHS
tudy population (9).
onclusions
his and other recent studies provide strong evidence for
he superiority of central BP, particularly PP, to brachial BP
Figure 2 Box Plots of Brachial PP per
Quartile of Central Aortic PP
Box plots (median, quartiles, and range) of brachial pulse pressure (PP) strati-
fied by quartile of central aortic PP demonstrate substantial overlap of brachial
PP values across quartiles and highlight the inability to accurately estimate
central pressure from brachial pressure.
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Central Pulse Pressure and Cardiovascular Outcome October 27, 2009:1730–4n correlation with subclinical vascular disease and associa-
ion with CVD events. Furthermore, preliminary evidence
uggests that achievement of a lower central BP for a given
evel of brachial BP may be more effective in reducing CVD
arget organ damage and morbidity and mortality. These
ndings lend strong support for prospective examination of
entral BP thresholds for prediction of CVD events and
otential treatment targets in future trials (21).
eprint requests and correspondence: Dr. Mary J. Roman,
ivision of Cardiology, Weill Cornell Medical College, 525 East
8th Street, New York, New York 10021. E-mail: mroman@
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